Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal fentanyl for episodic breathlessness in hospice patients with terminal non-malignant disease
ACTRN12617001399381Phase 2Completed
- Sponsor
- MedicalDirector
- Start
- Jul 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of fentanyl in Dyspnoea (SOB) (2 arms), sponsored by MedicalDirector. Primary endpoint: Change in Visual analogue dyspnea scale at 15 minutes. Started Jul 2018; status: completed.
02
Drugs
fentanyl
03
Conditions
Dyspnoea (SOB)
Beyond the preview
Go deeper on ACTRN12617001399381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617001399381.